High-Risk Localized and Locally Advanced Prostate Cancer

Around 20%-30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of "high-risk" may need to be validated first. Although recent advances in radiotherapy for prostate cancer have yielded excellent long-term results, even in high-risk localized disease, there are no studies directly comparing it with local treatment options, such as prostatectomy. To address current challenges in high-risk localized and locally advanced prostate cancer, 12 original and 3 review articles covering aspects from basic research to clinical trials are published in this Special Issue.

• Format: Hardcover
• Language: English
• ISBN: 3036581685
• ISBN13: 9783036581682
• Release Date: July 2023
• Publisher: Mdpi AG
• Length: 244 Pages
• Weight: 1.60 lbs.
• Dimensions: 0.8" x 6.7" x 9.6"